As cervical cancer screening transitions to primary human papillomavirus (HPV) testing, effective triage and management of HPV-positive women is critical to avoid unnecessary colposcopy referral and associated harms while maintaining high sensitivity for cervical precancer. Triage with p16/Ki-67 dual-stain (DS) testing has shown high sensitivity and specificity for detection of cervical precancers; however, longitudinal studies are needed to determine the long-term risk of precancer following a negative DS result. EXPOSURES All p16/Ki-67 DS testing was performed on residual SurePath material, and slides were evaluated for p16/Ki-67 positivity.
H uman papillomavirus (HPV) testing has been approved for primary cervical cancer screening. Efficient management of HPV-positive women requires triage markers that distinguish those at high risk who need colposcopy from those who can safely return to routine screening. 1, 2 Currently, Papanicolaou testing (hereinafter "cytology") alone or in combination with HPV genotyping is recommended for triage of HPV-positive women in some settings 3 ; however, cytology requires frequent testing at shorter intervals because the risk of precancer in cytology-negative women is not low enough to provide long-term reassurance. 4 To overcome these limitations, alternative molecular-based markers are currently being evaluated, including p16/Ki-67 dual stain (DS) testing, which detects coexpression of p16, a tumor suppressor protein upregulated by HPV oncogene activity, and the cell proliferation marker Ki-67. [5] [6] [7] [8] [9] [10] [11] [12] We and others have
shown that p16 and DS testing have better performance than cytology for detection of precancers in HPV-positive women. 6, 8, 10, 11, 13 Longitudinal studies are needed to establish optimal testing intervals for DS-negative women. To our knowledge, only 1 study has evaluated the longitudinal accuracy of p16, showing high sensitivity of p16 for cervical precancer for up to 3 years. 13 However, prospective studies evaluating DS for HPV triage are lacking. Herein, we evaluate the 5-year risk of cervical precancer following DS triage of HPV-positive women undergoing screening.
Methods

Study Population
This is a prospective cohort study of women undergoing cervical cancer screening with cytology and HPV co-testing at Kaiser Permanente Northern California (KPNC). 6 Between January and May of 2012, discard SurePath cytology specimens were collected at KPNC from 2364 HPV-positive women 30 years and older. Disease end points were abstracted from electronic medical records through May 2017. We excluded 544 women with a previous abnormal cytology within 2 years of enrollment, leaving 1820 HPV-positive women. We further excluded 150 women who did not have an evaluable DS result, 81 missing follow-up, and 40 women who had indeterminate outcomes. These 271 excluded women were similar in age, but had a higher proportion of normal cytology results compared with the 1549 (85.1% of the 1820) women included in the analysis (70% vs 49%, P < .001). The study was approved by the KPNC institutional review board and a waiver of informed consent was granted. This study was exempt from institutional review at the National Cancer Institute.
Cytology and HPV Testing
SurePath slides (Becton Dickinson) were prepared, stained, and processed on the FocalPoint Slide Profiler (Becton, Dickinson and Company). Cytology was categorized per the 2001 Bethesda System as negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), and high-grade squamous intraepithelial lesion (HSIL). 14 The HPV testing was performed using Hybrid Capture 2 (HC2; Qiagen Inc) in specimen transport medium at the KPNC regional laboratory per the manufacturer's instructions. All HPV-positive women were evaluated by guided screening-assisted screening and full manual review with knowledge of HPV status. All abnormal slides were sent for pathology review. In addition, all negative cytology results from HPV-positive women were rescreened manually. Management was not based on DS results.
p16/Ki-67 Dual Staining
All p16/Ki-67 DS testing was performed on the residual SurePath cell pellet, supplemented with CytoRich Fluid (Becton, Dickinson and Company) within 1 to 4 months of sample collection. Slides were produced at the manufacturer's laboratory using the CINtec PLUS Cytology kit (Roche) according to instructions, with each staining run including 2 control specimens. Staining was performed on a Dako Autostainer using the program for SurePath slides, followed by hematoxylin counterstaining. Slides were evaluated by an expert cytotechnologist blinded to the associated cervical histology; the number of DS-positive cells was assessed semiquantitatively (0, 1, 2-5, 6-50, or >50).
Follow-up and Ascertainment of Disease End Points
At KPNC, women who tested HPV-positive with ASC-US or more severe cytologic abnormalities (≥ASC-US) were referred for colposcopy, while women who tested HPV-positive with NILM cytology underwent repeated co-testing after 12 months and were referred for colposcopy if either test result was positive. Histological diagnoses are based on the cervical intraepithelial neoplasia (CIN) classification.
intervals (95% CI) of ≥CIN2 and ≥CIN3 by enrollment DS (positive vs negative) and cytology (≥ASC-US vs NILM) individually, and as combined categories, and fit separate models stratified by age (<45 years vs ≥45 years). We also evaluated cumulative risks of ≥CIN2 and ≥CIN3 by number of DS-positive cells (1, 2-5, 6-50, or >50 vs 0) and cytology categories (ASC-US, LSIL, or ≥HSIL vs NILM). Risks were estimated using a logistic Weibull model (eMethods and eFigure 1 in the Supplement). 15,16 P values were calculated using t tests. For comparison, we also report cumulative detection using the Kaplan-Meier method (eFigures 2-5 in the Supplement). Risks were compared with internal benchmarks in our study population, estimated as the baseline (1-year) risk of ≥CIN2 and ≥CIN3 in HPV-positive women with ASC-US (threshold for immediate colposcopy referral, 11.1% and 5.7%, respectively) and in HPV-positive women with NILM (threshold for a 1-year return, 6.2% and 3.1%, respectively). Analyses were performed with R software (version 3.3.1) and logistic Weibull models were estimated using the PIMixture package. 16 All statistical tests were 2-sided with P < .05 considered significant.
Results
Study Population
Among the 1549 HPV-positive women included, the mean age at enrollment was 42.2 years, and the median follow-up time was 3.7 years (range, 0.2-5.4 years). A total of 11 women were diagnosed with cancer, 110 with CIN3, 12 with adenocarcinoma in situ, 108 with CIN2, and the remaining 1308 were <CIN2 ( Figure 1 and eTable 1 in the Supplement). Among those with ≥CIN2, 137 were prevalent cases with a median time to diagnosis of 1.6 months, and 71 were incident cases with a median time to diagnosis of 34.8 months. Among the remaining 33 cases with unknown prevalent or incident ≥CIN2, the median time to diagnosis was 20.4 months.
DS Positivity by Cytology and Histology Results
A total of 705 women (45.5%) were DS positive, and 785 (50.7%) had ≥ASC-US cytology at baseline. The DS positivity increased with worsening cytologic severity from 32% in women with NILM to 83% in women with >HSIL (P < .001 for trend). Similarly, DS positivity increased with increasing severity of worst histologic diagnosis from 22% in women without biopsy to 77% in women with CIN3, and 91% in women with cancer (P < .001 for trend) (eTable 1 in the Supplement). Figure 3 ). The baseline and 5-year risks of ≥CIN2 in women with DS-negative/≥ASC-US findings (5.3%; 95% CI, 3.4%-8.3% and 10.0%; 95% CI, 6.7%-14.8%, respectively) were similar to those with DS-negative/NILM cytology (3.2%; 95% CI, 2.0%-5.2% and 7.6%; 95% CI, 5.2%-11.0%, respectively). We observed similar patterns for risk of ≥CIN3 (eTable 2 in the Supplement) and did not observe any significant differences by age (data not shown). The baseline and cumulative 5-year risks of ≥CIN2 and ≥CIN3 increased with increasing number of DS-positive cells, providing additional levels of risk stratification compared with categories of cytology (eTable 3 and eFigure 6 in the Supplement).
Long-Term Risk Stratification by DS and Cytology Compared With Internal Benchmarks
Cumulative risks of ≥CIN2 and ≥CIN3 in DS-positive women and in women with ≥ASC-US were much higher than internal risk thresholds for colposcopy referral for all 5 years. In DSnegative women, cumulative risks of ≥CIN2 and ≥CIN3 remained below the colposcopy referral threshold for up to 5 years and crossed the 1-year return referral threshold at year 3, respectively. In contrast, cumulative risks of ≥CIN2 and ≥CIN3 in women with NILM cytology crossed the threshold for immediate colposcopy referral after year 4 and the 1-year return risk threshold at year 1, respectively ( Figure 2 ). The combination of DS and cytology provided long-term risk stratification: risks of ≥CIN2 and ≥CIN3 in women with ≥ASC-US who were DS negative were lower than the colposcopy referral threshold for all 5 years. In contrast, the risks of ≥CIN2 and ≥CIN3 in women with NILM cytology who were DS positive were higher than the colposcopy referral threshold at baseline ( Figure 3 ).
Discussion
As cervical cancer screening transitions to primary HPV testing, finding effective triage and management for HPVpositive women remains a critical issue. 
DS-/≥ASC-US
The 5-year cumulative risk curves were generated using the logistic Weibull model. The dashed line corresponds to the threshold for a 1-year return, and the dotted line corresponds to the threshold for immediate colposcopy referral in this study population. Plus sign indicates positive; minus sign, negative; ASC-US, atypical squamous cells of undetermined significance; CIN2, cervical intraepithelial neoplasia grade of 2; CIN3, CIN grade of 3; NILM, negative for intraepithelial lesion or malignancy.
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positivity, and can provide superior long-term risk stratification than cytology and HPV co-testing, which may reduce costs associated with screening and management.
Results from our analysis of DS positivity thresholds suggest that additional risk stratification can be obtained from quantitative assessment of DS-positive cells. The risk of precancer in women with more than 50 positive cells approached the risk of HSIL, and it is possible that automated evaluation may enable even more refined risk stratification compared with the current semiquantitative, manual approach.
19
To our knowledge, ours is the first study to evaluate the longterm performance of DS for triage of HPV-positive women. Previously, Carozzi et al 13 assessed the 3-year performance of p16 staining in a prospective study nested within the New Technologies for Cervical Cancer Screening (NTCC) trial. In their study, p16 cytology provided long-term risk stratification and had high longitudinal sensitivity for cervical precancer over 3 years. Compared with their estimates, the 3-year risks of ≥CIN2 and ≥CIN3 found in the present study were slightly higher. In the NTCC trial, HPV-positive women were referred for colposcopy, with annual follow-up until clearance of HPV was observed. Thus, differences in underlying population characteristics, frequency of disease ascertainment, and methodological approaches for estimating risk may account for these differences.
Strengths and Limitations
Strengths of our analysis include a large population, providing precise risk estimates particularly for the long-term reassurance against ≥CIN2 of DS-negative results. Further, the uniform screening and management procedures assured excellent outcome ascertainment with little loss to follow-up over 5 years. Our study reflects real-world clinical practice in an organized setting, which is essential for informing screening guidelines.
A potential limitation of our study for evaluating baseline risk was the differential management of HPV-positive women with ≥ASC-US vs those with NILM cytology, and the fact that referral was not based on DS. To address this, we used logistic Weibull models, which accounted for undiagnosed prevalent disease that may have occurred in women testing HPV positive and NILM who were not immediately referred for colposcopy. 15, 16 This approach provided more accurate risk estimates compared with other commonly used methods such as Kaplan-Meier and enabled better estimation of prevalent precancer risk.
Conclusions
In conclusion, our prospective study of HPV-positive women undergoing cervical cancer screening shows that DS provides long-term risk stratification compared with cytology triage for up to 5 years. Since the risk of precancer in HPV-positive/ DS-negative women is identical at 3 years to the risk in women who test HPV positive and cytology NILM at 1 year, repeated testing can be safely extended to 3-year intervals in these women. 
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© 2018 American Medical Association. All rights reserved. Women were classified as disease free if the worst biopsy was <CIN2 or when the last follow-up co-test was negative. Women were assumed to have prevalent CIN2+ if they were diagnosed at colposcopy following the enrollment co-test and prior to the next co-test, otherwise CIN2+ was assumed to have occurred in the interval between the last disease-free time point and the time of diagnosis. For women diagnosed with CIN2+ without a prior disease-free time point (such as women with CIN2+ who were HPVpositive with NILM cytology at baseline), we allowed for the possibility that the CIN2+ may have been prevalent.
Prevalence-Incidence Mixture Models
We used the Logistic Weibull model to estimate cumulative risks and 95% confidence intervals (CI). Cervical cancer screening data from routine clinical practice, such as Kaiser Permanente Northern California (KPNC), have features that must be accounted for to produce comparable absolute risk estimates for onset of clinically detectable CIN2+ or CIN3+. First, the time of onset, T, for a woman is unobserved and known only to fall between screens in which the disease status was definitively ascertained (interval-censoring). We considered disease status to have been definitively ascertained if the woman has a colposcopy visit or has a screening visit that effectively rules out CIN2+ (eg. negative by both HPV and cytology). Screening results positive by either HPV or cytology without follow-up colposcopy visits are considered to be visits in which disease was not definitively ascertained (n=40).
Second, women may have prevalent disease present at the initial screen. Prevalent disease is not always immediately diagnosed (e.g., in KPNC, women who are HPV-positive for the first time are typically not referred to colposcopy unless they also have a positive cytology result), and thus some disease found at later screens are actually missed prevalent disease. The Logistic Weibull model accounts for prevalent disease at enrollment, incident disease occurring between screening visits, and for the possibility that some disease found during follow-up may have been undiagnosed prevalent disease (i.e., unknown prevalent or incident).
eFigure 1: Example screening data from electronic health records (EHRs) for 9 women. Women become susceptible to disease (start of dashed lines) at some point before enrollment (vertical dotted line), may acquire clinically-detectable disease (denoted with x) and then may be subsequently diagnosed (solid circles). Disease status is known only at specific times (unfilled circles represent known disease-free status; solid circles represent known diseased status).
Kaplan-Meier methods were initially developed for estimation of mortality risks 1 and cannot estimate unbiased absolute risks for asymptomatic disease 2 , except in clinical trial setting where all subjects return at fixed intervals 3 . When applied to screening data, Kaplan-Meier methods will tend to underestimate risks at early time points, because it assumes that the time of disease detection is the time of disease onset, and overestimate risks at later time points, because relatively more disease is found later when risk sets are thinner due to censoring 2, 4 . Underestimation and overestimation of the KaplanMeier risks can be seen in eFigures 2-5.
Instead, we estimated the risk of disease onset using a logistic-Weibull prevalence-incidence mixture model 4 . The Weibull survival model is a proportional hazard model with a Weibull baseline distribution, which is suggested by the multi-stage model for carcinogenesis 5 , and naturally handles interval censoring of disease onset. By jointly fitting the logistic regression and Weibull survival model components as a mixture model, we can account for unknown prevalent disease status.
The logistic-Weibull risk estimates were visually compared to the non-parametric risk estimates 4 to ensure that the Weibull parametric assumption was appropriate. The non-parametric risk for screening data is the Turnbull method for interval-censored time to event data 6 adapted to handle undiagnosed prevalent disease. It is a step function with large jumps and cannot handle covariates, so its primary usefulness is in checking the parametric assumptions of prevalence-incidence mixture models. Using © 2018 American Medical Association. All rights reserved.
parametric assumptions allows for smoother risk curves and for comparison of screening methods using time-specific risk estimates.
We briefly describe risk estimation for the logistic-Weibull prevalence-incidence mixture models.
Given covariate values x, the cumulative risk at time t (where t=0 is baseline) can be modelled as the sum of the probability of having prevalent disease at baseline and the probability of developing incident disease after baseline:
where is a logistic regression model with regression coefficients , ,
and is a Weibull survival model with regression coefficients and shape parameter ,
We call the combined model a logistic-Weibull prevalence-incidence mixture model. 10.0% [95% CI, 6.7-14.5%], respectively) were not statistically significantly higher compared to those with p16/Ki-67 DS-negative/NILM cytology. We observed similar statistically significant patterns for risk of CIN3+ (eTable2) and did not observe any significant differences by age (data not shown).
